@FiercePharma: Daiichi to take over Ranbaxy unit's marketing in Venezuela, latest "hybrid business model" move to make buyout pay off. More | Follow @FiercePharma
> Shares of U.K. drugmaker AstraZeneca ($AZN) jumped Tuesday after a Liberum Capital analyst suggested that it would be the perfect merger partner for Abbott's ($ABT) planned spinoff AbbVie. Story
> Ranbaxy Laboratories, which is operating under an extensive consent decree with U.S. regulators, has been given a four-day suspension from authorities in India for "flouting" rules for storing products. Story
> India used the BIO 2012 conference to release new "similar biologics" guidelines that will require manufacturers of biosimilars to prove similarity within four years of postmarket safety data to either a drug licensed in India or one approved elsewhere. Story
> Ranbaxy Laboratories, which had used a local distributor to market its drugs in Venezuela, is turning that responsibility over to Daiichi Sankyo. Item
> On the same day that news broke that the FDA user fee reauthorization bill would not contain provisions for a track-and-trace program, the FDA announced that it intended to continue a proof-of-concept program for securing the drugmaking supply chain. Story
> CDMO AMRI ($AMRI) CFO Mark Frost says the company is looking to further cut operations in the U.S. as it braces for patent losses that will hurt its revenue. Story
Biotech News
@FierceBiotech: Check out our live coverage of BIO 2012 in Boston. More | Follow @FierceBiotech
@JohnCFierce: Tesaro sets IPO terms, looks to raise about $81M, with $25M maybe coming from insiders - I'd like to see this one work. More | Follow @JohnCFierce
@RyanMFierce: Thanks @Millennium_US, Shire, and Biogen for participating on our BIO 2012 panel. We drew a crowd and covered a lot. | Follow @RyanMFierce
> Investors offer grim odds of success for two big Alzheimer's programs. Story
> Tesaro insiders pledge support for $86M IPO gamble. Article
> Biotech employment, salaries weather a stormy economic downturn. News
Medical Devices News
@FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev
> Exclusive: Allegro Diagnostics is raising a $15M-$20M Series B round. Story
> Expect steady growth for the urological devices market. More
> Bard pours $40M-plus into Puerto Rican device production expansion. News
Drug Delivery News
@DamianFierce: Drugmakers are rethinking drug delivery methods for multiple sclerosis treatments. Report | Follow @DamianFierce
> Notre Dame's nanoparticles effective against drug-resistant cancer. Story
> Ambrx nabs $303M deal with Merck for 'smart bomb' delivery. Article
> TheStreet: Alkermes should stick to drug delivery. More
> Explosive nanocarriers thwart target cells' defenses. News
Biomarkers News
> Blood test for pancreatic cancer may be possible. Story
> Huntington's disease marker emerges in clinical trial. News
> Biodesix feels the buzz at BIO2012. Article
And Finally... Forest ($FRX) CEO Howard Solomon, whose company faces a proxy fight with Carl Icahn and the loss of patents on its best-selling drug, Lexapro, told financial analysts Wednesday that the company's future looks good. Story